{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12224"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12224","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"CD20+ T cells: phenotype, origin and presence in the tumour microenvironment","abstract":"CD20 is well-known as a lineage marker for B cells in human, although the presence of CD20+ T cells has been reported previously (Schuh et al., 2016). In my experiments we sorted memory CD8+CD20+ and CD20- T cells and subsequently analysed TCRβ CDR3 sequences to determine clonal overlap between populations. I was able to demonstrate TCRβ CDR3 amino acid sequences within the CD20+ T cells that were not found in the CD20- T cells population, suggesting the presence of unique T cell clones. This data suggests possible thymic origin of at least some CD20+ T cells, or an early expression of CD20+ following activation of naïve T cells. This does not however refute the trogocytosis theory where some T cells acquire CD20 from B cell. I analysed a number of published mass cytometry datasets and determined that memory CD20+ T cells express higher levels of CD127, CD27, CD28, PD-1 and CD57 especially by the effector memory (Tem) and effector memory CD45RA revertant (Temra) subsets, suggesting a possible late differentiation state of the CD20+ T cells. Further phenotyping revealed a novel population of CD20+Vα7.2+CD161+ cells in the peripheral blood of healthy donors, which are potentially CD20+ mucosal-invariant T (MAIT) cells. In colon cancer, CD20+ T cells were found within tumour tissue, adjacent normal tissue and showed fewer CD20+ T cells expressing the marker CD39. This may indicate lower numbers of CD20+ T cells within tumour-reactive T cell pool and requires further investigation. Using mass cytometry datasets from colorectal cancer patients, and melanoma patients receiving anti- programmed cells death (PD-1) or anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4), CD20+ T cells showed similar phenotypes to those found in healthy peripheral blood. Importantly, they produced higher levels of cytokines compared to the CD20- T cells including; TNF-α, IFN-γ, IL-2, IL-17, and MIP-1β. My data, including both primary data and analysis of published datasets, indicates that CD20+ T cells can originate as a separate lineage, in addition to acquiring CD20 by trogocytosis. CD20+ T cells were found to be more highly differentiated, with increased cytokine production and contained a high frequency of CD20+ Vα7.2+CD161+ cells. Although there was no detectable difference in cancer, future work will be required to determine if they play any role within the tumour microenvironment or other pathological scenarios.","abstract_html":"CD20 is well-known as a lineage marker for B cells in human, although the presence of CD20+ T cells has been reported previously (Schuh et al., 2016). In my experiments we sorted memory CD8+CD20+ and CD20- T cells and subsequently analysed TCRβ CDR3 sequences to determine clonal overlap between populations. I was able to demonstrate TCRβ CDR3 amino acid sequences within the CD20+ T cells that were not found in the CD20- T cells population, suggesting the presence of unique T cell clones. This data suggests possible thymic origin of at least some CD20+ T cells, or an early expression of CD20+ following activation of naïve T cells. This does not however refute the trogocytosis theory where some T cells acquire CD20 from B cell. I analysed a number of published mass cytometry datasets and determined that memory CD20+ T cells express higher levels of CD127, CD27, CD28, PD-1 and CD57 especially by the effector memory (Tem) and effector memory CD45RA revertant (Temra) subsets, suggesting a possible late differentiation state of the CD20+ T cells. Further phenotyping revealed a novel population of CD20+Vα7.2+CD161+ cells in the peripheral blood of healthy donors, which are potentially CD20+ mucosal-invariant T (MAIT) cells. In colon cancer, CD20+ T cells were found within tumour tissue, adjacent normal tissue and showed fewer CD20+ T cells expressing the marker CD39. This may indicate lower numbers of CD20+ T cells within tumour-reactive T cell pool and requires further investigation. Using mass cytometry datasets from colorectal cancer patients, and melanoma patients receiving anti- programmed cells death (PD-1) or anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4), CD20+ T cells showed similar phenotypes to those found in healthy peripheral blood. Importantly, they produced higher levels of cytokines compared to the CD20- T cells including; TNF-α, IFN-γ, IL-2, IL-17, and MIP-1β. My data, including both primary data and analysis of published datasets, indicates that CD20+ T cells can originate as a separate lineage, in addition to acquiring CD20 by trogocytosis. CD20+ T cells were found to be more highly differentiated, with increased cytokine production and contained a high frequency of CD20+ Vα7.2+CD161+ cells. Although there was no detectable difference in cancer, future work will be required to determine if they play any role within the tumour microenvironment or other pathological scenarios.","abstract_has_math":false,"creators":["Suliman, Muath Mohammed"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-07","date_published":"2022-07","updated_at":"2026-11-19T09:31:41Z","subjects":["QR180 Immunology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12224/7/Suliman2022PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12224","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Suliman, Muath Mohammed"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-07"]},{"key":"dc:date.issued","label":"Date","values":["2022-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12224/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12224/7/Suliman2022PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["CD20 is well-known as a lineage marker for B cells in human, although the presence of CD20+ T cells has been reported previously (Schuh et al., 2016). In my experiments we sorted memory CD8+CD20+ and CD20- T cells and subsequently analysed TCRβ CDR3 sequences to determine clonal overlap between populations. I was able to demonstrate TCRβ CDR3 amino acid sequences within the CD20+ T cells that were not found in the CD20- T cells population, suggesting the presence of unique T cell clones. This data suggests possible thymic origin of at least some CD20+ T cells, or an early expression of CD20+ following activation of naïve T cells. This does not however refute the trogocytosis theory where some T cells acquire CD20 from B cell. I analysed a number of published mass cytometry datasets and determined that memory CD20+ T cells express higher levels of CD127, CD27, CD28, PD-1 and CD57 especially by the effector memory (Tem) and effector memory CD45RA revertant (Temra) subsets, suggesting a possible late differentiation state of the CD20+ T cells. Further phenotyping revealed a novel population of CD20+Vα7.2+CD161+ cells in the peripheral blood of healthy donors, which are potentially CD20+ mucosal-invariant T (MAIT) cells. In colon cancer, CD20+ T cells were found within tumour tissue, adjacent normal tissue and showed fewer CD20+ T cells expressing the marker CD39. This may indicate lower numbers of CD20+ T cells within tumour-reactive T cell pool and requires further investigation. Using mass cytometry datasets from colorectal cancer patients, and melanoma patients receiving anti- programmed cells death (PD-1) or anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4), CD20+ T cells showed similar phenotypes to those found in healthy peripheral blood. Importantly, they produced higher levels of cytokines compared to the CD20- T cells including; TNF-α, IFN-γ, IL-2, IL-17, and MIP-1β. My data, including both primary data and analysis of published datasets, indicates that CD20+ T cells can originate as a separate lineage, in addition to acquiring CD20 by trogocytosis. CD20+ T cells were found to be more highly differentiated, with increased cytokine production and contained a high frequency of CD20+ Vα7.2+CD161+ cells. Although there was no detectable difference in cancer, future work will be required to determine if they play any role within the tumour microenvironment or other pathological scenarios."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["CD20+ T cells: phenotype, origin and presence in the tumour microenvironment"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Suliman, Muath Mohammed"],"dc:date":["2022-07"],"dc:date.issued":["2022-07"],"dc:description.abstract":["CD20 is well-known as a lineage marker for B cells in human, although the presence of CD20+ T cells has been reported previously (Schuh et al., 2016). In my experiments we sorted memory CD8+CD20+ and CD20- T cells and subsequently analysed TCRβ CDR3 sequences to determine clonal overlap between populations. I was able to demonstrate TCRβ CDR3 amino acid sequences within the CD20+ T cells that were not found in the CD20- T cells population, suggesting the presence of unique T cell clones. This data suggests possible thymic origin of at least some CD20+ T cells, or an early expression of CD20+ following activation of naïve T cells. This does not however refute the trogocytosis theory where some T cells acquire CD20 from B cell. I analysed a number of published mass cytometry datasets and determined that memory CD20+ T cells express higher levels of CD127, CD27, CD28, PD-1 and CD57 especially by the effector memory (Tem) and effector memory CD45RA revertant (Temra) subsets, suggesting a possible late differentiation state of the CD20+ T cells. Further phenotyping revealed a novel population of CD20+Vα7.2+CD161+ cells in the peripheral blood of healthy donors, which are potentially CD20+ mucosal-invariant T (MAIT) cells. In colon cancer, CD20+ T cells were found within tumour tissue, adjacent normal tissue and showed fewer CD20+ T cells expressing the marker CD39. This may indicate lower numbers of CD20+ T cells within tumour-reactive T cell pool and requires further investigation. Using mass cytometry datasets from colorectal cancer patients, and melanoma patients receiving anti- programmed cells death (PD-1) or anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4), CD20+ T cells showed similar phenotypes to those found in healthy peripheral blood. Importantly, they produced higher levels of cytokines compared to the CD20- T cells including; TNF-α, IFN-γ, IL-2, IL-17, and MIP-1β. My data, including both primary data and analysis of published datasets, indicates that CD20+ T cells can originate as a separate lineage, in addition to acquiring CD20 by trogocytosis. CD20+ T cells were found to be more highly differentiated, with increased cytokine production and contained a high frequency of CD20+ Vα7.2+CD161+ cells. Although there was no detectable difference in cancer, future work will be required to determine if they play any role within the tumour microenvironment or other pathological scenarios."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12224/7/Suliman2022PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12224/"],"dc:subject":["QR180 Immunology"],"dcterms:accessrights":["public"],"dc:title":["CD20+ T cells: phenotype, origin and presence in the tumour microenvironment"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:41Z"}